|Description||ARRY-403 is an orally available Glucokinase stimulants originated by Array BioPharma. ARRY-403 activates human glucokinase in vitro with EC50 of 79 nM at 5 mM glucose and Vmax = 134% compared to the no activator control. It exhibits good in vitro drug-like properties and selectivity against broad panels of receptors and enzymes. But，treatment for Type 2 diabetes mellitus was discontinued.|
|Solubility||Soluble in DMSO|
|Application||Type 2 diabetes mellitus|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Array BioPharma|
RO 28-0450 is a glucokinase GK agonist.
This active molecular is a hepatoselective glucokinase activator that reduces MDG (mean daily glucose), FPG (fasting plasma glucose) and glucose excursion in hu...
AM-2394 is a selective Glucokinase agonist (GKA), It activates GK with an EC50 value of 60 nM. AM-2394 increases the affinity of GK for glucose by approximately...
ARRY-403 is an orally available Glucokinase stimulants originated by Array BioPharma. ARRY-403 activates human glucokinase in vitro with EC50 of 79 nM at 5 mM g...
GKA 50 is a potent glucokinase activator (EC50 = 33 nM). It causes a decrease in plasma glucose levels in diabetic rats and an increase of insulin release from ...
LY2608204 activates glucokinase (GK) with EC50 of 42 nM at 10 mM glucose with a concentration dependent manner at lower glucose concentrations.
This active molecular is a glucokinase activator originated by Pfizer and EC50 value is 174 nM. PF-04937319 can improve glycemic control in adults with type 2 d...
AM-9514 is a glucokinase (GK) activator. It shows a favorable combination of in vitro potency, enzyme kinetic properties, acceptable pharmacokinetic profiles in...